ABSTRACT
Leptomeningeal disease (LMD) is well described in patients with brain metastases, presenting symptomatically in approximately 5% of patients. Conventionally, the presence of LMD is an indication for whole brain radiation therapy (WBRT) and not suitable for stereotactic radiosurgery (SRS). The purpose of the study was to evaluate the local control and overall survival of patients who underwent SRS to focal LMD. We reviewed our prospective registry and identified 32 brain metastases patients with LMD, from a total of 465 patients who underwent SRS between 2013 and 2015. Focal LMD was targeted with SRS in 16 patients. The median imaging follow-up time was 7 months. The median volume of LMD was 372 mm3 and the median margin dose was 16 Gy. Five patients underwent prior WBRT. Histology included non-small cell lung (8), breast (5), melanoma (1), gastrointestinal (1) and ovarian cancer (1). Follow-up MR imaging was available for 14 patients. LMD was stable in 5 and partially regressed in 8 patients at follow-up. One patient had progression of LMD with hemorrhage 5 months after SRS. Seven patients developed distant LMD at a median time of 7 months. The median actuarial overall survival from SRS for LMD was 10.0 months. The 6-month and 1-year actuarial overall survival was 60% and 26% respectively. Six patients underwent WBRT after SRS for focal LMD at a median time of 6 months. Overall, focal LMD may be may be treated successfully with radiosurgery, potentially delaying WBRT in some patients.
Subject(s)
Brain Neoplasms/complications , Meningeal Neoplasms/etiology , Meningeal Neoplasms/surgery , Meninges/surgery , Radiosurgery/methods , Adult , Aged , Brain Neoplasms/diagnostic imaging , Brain Neoplasms/secondary , Cranial Irradiation , Female , Follow-Up Studies , Humans , Kaplan-Meier Estimate , Magnetic Resonance Imaging , Male , Meningeal Neoplasms/diagnostic imaging , Meninges/diagnostic imaging , Middle Aged , Retrospective StudiesABSTRACT
Despite the successful FDA approval of sorafenib as the standard of care therapy in patients with advanced hepatocellular carcinoma (HCC), its clinical benefits have been modest. The mortality rate remains high and prognosis poor for patients with advanced-stage HCC. The exact mechanism of sorafenib in the treatment of HCC and its resistance at the molecular levels are largely unknown. There are no other treatment options in first-line therapy and there is currently no standard of care second-line therapies available. Thus, there is a critical need for novel therapeutic approaches for the treatment of advanced HCC, and thus a clear justification for the already reported, currently ongoing, and planned clinical trials.
Subject(s)
Carcinoma, Hepatocellular/drug therapy , Clinical Trials as Topic , Liver Neoplasms/drug therapy , Antineoplastic Agents/therapeutic use , Biological Products/therapeutic use , Carcinoma, Hepatocellular/pathology , Drug Therapy, Combination , Humans , Liver Neoplasms/pathology , Neoplasm StagingABSTRACT
Cytotoxic T lymphocytes (CTLs) are critical for the control of human immunodeficiency virus, but containment of virus replication can be undermined by mutations in CTL epitopes that lead to virus escape. We analyzed the evolution in vivo of an immunodominant, HLA-A2-restricted CTL epitope and found two principal, diametrically opposed evolutionary pathways that exclusively affect T cell-receptor contact residues. One pathway was characterized by acquisition of CTL escape mutations and the other by selection for wild-type amino acids. The pattern of CTL responses to epitope variants shaped which variant(s) prevailed in the virus population. The pathways notably influenced the amount of plasma virus, as patients with efficient CTL selection had lower plasma viral loads than did patients without efficient selection. Thus, viral escape from CTL responses does not necessarily correlate with disease progression.
Subject(s)
HIV Antigens/genetics , HIV-1/genetics , HIV-1/immunology , Receptors, Antigen, T-Cell/metabolism , Adult , Amino Acid Sequence , Crystallography, X-Ray , Evolution, Molecular , Female , Gene Products, gag/chemistry , Gene Products, gag/genetics , Gene Products, gag/immunology , Genetic Variation , HIV Antigens/metabolism , HIV Infections/immunology , HIV Infections/virology , HLA-A2 Antigen/chemistry , HLA-A2 Antigen/metabolism , Humans , Immunodominant Epitopes/genetics , Immunodominant Epitopes/metabolism , Models, Molecular , Molecular Sequence Data , Multiprotein Complexes , Mutation , Peptide Fragments/chemistry , Peptide Fragments/genetics , Peptide Fragments/immunology , Phylogeny , Selection, Genetic , T-Lymphocytes, Cytotoxic/immunology , Viremia/immunology , Viremia/virology , env Gene Products, Human Immunodeficiency VirusABSTRACT
All thymically selected T cells are inherently cross-reactive, yet many data indicate a fine specificity in antigen recognition, which enables virus escape from immune control by mutation in infections such as the human immunodeficiency virus (HIV). To address this paradox, we analyzed the fine specificity of T cells recognizing a human histocompatibility leukocyte antigen (HLA)-A2-restricted, strongly immunodominant, HIV gag epitope (SLFNTVATL). The majority of 171 variant peptides tested bound HLA-A2, but only one third were recognized. Surprisingly, one recognized variant (SLYNTVATL) showed marked differences in structure when bound to HLA-A2. T cell receptor (TCR) recognition of variants of these two peptides implied that they adopted the same conformation in the TCR-peptide-major histocompatibility complex (MHC) complex. However, the on-rate kinetics of TCR binding were identical, implying that conformational changes at the TCR-peptide-MHC binding interface occur after an initial permissive antigen contact. These findings have implications for the rational design of vaccines targeting viruses with unstable genomes.
